TGTX Tg Therapeutics Inc
Price (delayed)
$37.12
Market cap
$5.83B
P/E Ratio
232
Dividend/share
N/A
EPS
$0.16
Enterprise value
$5.9B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
The company's net income has surged by 85% YoY
Tg Therapeutics's EPS has surged by 78% YoY
The quick ratio has increased by 33% QoQ but it has decreased by 3% YoY
TGTX's debt has soared by 131% YoY
The gross margin has decreased by 6% YoY
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
157.07M
Market cap
$5.83B
Enterprise value
$5.9B
Price to earnings (P/E)
232
Price to book (P/B)
25.99
Price to sales (P/S)
16.4
EV/EBIT
118.94
EV/EBITDA
118.77
EV/Sales
17.94
Revenue
$329M
Gross profit
$290.52M
Operating income
$41.93M
Net income
$23.38M
EBIT
$49.62M
EBITDA
$49.69M
Free cash flow
-$40.56M
Per share
Balance sheet
Liquidity
EPS
$0.16
EPS diluted
$0.15
Free cash flow per share
-$0.28
Book value per share
$1.43
Revenue per share
$2.26
TBVPS
$3.98
Total assets
$577.69M
Total liabilities
$355.33M
Debt
$252.56M
Equity
$222.36M
Working capital
$475.68M
Debt to equity
1.14
Current ratio
6.25
Quick ratio
4.87
Net debt/EBITDA
1.44
Margins
Efficiency
Dividend
EBITDA margin
15.1%
Gross margin
88.3%
Net margin
7.1%
Operating margin
12.7%
Return on assets
4.8%
Return on equity
12.4%
Return on invested capital
11.7%
Return on capital employed
10.2%
Return on sales
15.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
-0.3%
1 week
5.48%
1 month
20.79%
1 year
135.98%
YTD
23.32%
QTD
23.32%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$329M
Gross profit
$290.52M
Operating income
$41.93M
Net income
$23.38M
Gross margin
88.3%
Net margin
7.1%
The operating income has soared by 103% YoY
The company's net income has surged by 85% YoY
Tg Therapeutics's operating margin has increased by 44% YoY
The revenue rose by 41% YoY and by 24% QoQ
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
232
P/B
25.99
P/S
16.4
EV/EBIT
118.94
EV/EBITDA
118.77
EV/Sales
17.94
Tg Therapeutics's EPS has surged by 78% YoY
The P/B is 49% above the last 4 quarters average of 17.5 and 18% above the 5-year quarterly average of 22.0
The equity is up by 39% year-on-year and by 16% since the previous quarter
The P/S is 100% below the 5-year quarterly average of 4680.7 but 60% above the last 4 quarters average of 10.3
The revenue rose by 41% YoY and by 24% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has increased by 37% YoY
The company's return on equity fell by 3.9% YoY
TGTX's ROIC is down by 2.5% YoY
The ROA has grown by 2.1% YoY
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 63% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 110% YoY but it has decreased by 10% QoQ
The total assets has soared by 75% YoY
TGTX's debt is 14% higher than its equity
TGTX's debt has soared by 131% YoY
The debt to equity has soared by 68% YoY but it has contracted by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.